| scholarly article | Q13442814 |
| P50 | author | Albert Pares | Q40418471 |
| David E. J. Jones | Q89209099 | ||
| Kris V. Kowdley | Q110296712 | ||
| P2093 | author name string | Catherine Vincent | |
| Gideon M Hirschfield | |||
| Luciano Adorini | |||
| Christian Rust | |||
| David Shapiro | |||
| Christoph Schramm | |||
| Velimir Luketic | |||
| Hanns-Ulrich Marschall | |||
| Roger Chapman | |||
| Andrew Mason | |||
| Raoul Poupon | |||
| Richard Pencek | |||
| Cathi Sciacca | |||
| Obeticholic Acid PBC Monotherapy Study Group | |||
| Olaf Böhm | |||
| Tessa Beecher-Jones | |||
| P2860 | cites work | The immunogenetics of primary biliary cirrhosis: A comprehensive review | Q26801377 |
| New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond | Q27013066 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation | Q34043010 | ||
| 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. | Q34143282 | ||
| The immunobiology and pathophysiology of primary biliary cirrhosis | Q34324185 | ||
| Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. | Q34453425 | ||
| Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. | Q34494216 | ||
| Systematic review: ursodeoxycholic acid--adverse effects and drug interactions | Q35583064 | ||
| Bile Acids as Hormones: The FXR-FGF15/19 Pathway | Q35737058 | ||
| Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis | Q36599248 | ||
| Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review | Q36714163 | ||
| Role of bile acids and bile acid receptors in metabolic regulation | Q37363616 | ||
| Predicting outcome in primary biliary cirrhosis | Q38220068 | ||
| Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. | Q38413146 | ||
| Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte | Q39642788 | ||
| The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. | Q40681087 | ||
| Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study | Q43471968 | ||
| Combined endpoints: can we use them? | Q44153771 | ||
| Natural history of pruritus in primary biliary cirrhosis | Q44797529 | ||
| A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis | Q45040478 | ||
| The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis | Q45134599 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans | Q50148264 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Primary biliary cirrhosis | Q57141930 | ||
| PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis | Q59384457 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome | Q84441124 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ascending cholangitis | Q603644 |
| P304 | page(s) | 1890-1902 | |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis | |
| P478 | volume | 67 |
| Q89623409 | Aging-Related Molecular Pathways in Chronic Cholestatic Conditions |
| Q91642444 | Bile Acid Biology, Pathophysiology, and Therapeutics |
| Q57111959 | Bile Acids Activated Receptors Regulate Innate Immunity |
| Q90274929 | Bile Acids as Metabolic Regulators and Nutrient Sensors |
| Q93028222 | CYP1A2 Downregulation by Obeticholic Acid: Usefulness as a Positive Control for the In Vitro Evaluation of Drug-Drug Interactions |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q91733388 | Current and potential treatments for primary biliary cholangitis |
| Q93046523 | Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials |
| Q49984619 | Evolving role of Obeticholic acid in primary biliary cholangitis |
| Q92163292 | Farnesoid X receptor and bile acids regulate vitamin A storage |
| Q57108085 | Fine-tuning of SIRT1 expression is essential to protect the liver from cholestatic liver disease |
| Q61803807 | Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis |
| Q92106425 | Intestinal Absorption of Bile Acids in Health and Disease |
| Q92685166 | Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study |
| Q57110523 | NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial |
| Q47223909 | New therapies target the toxic consequences of cholestatic liver disease |
| Q89623998 | New treatments/targets for primary biliary cholangitis |
| Q58562078 | Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis |
| Q52614648 | Novel Bile Acid Therapies for Liver Disease. |
| Q92404305 | Oxysterols and Gastrointestinal Cancers Around the Clock |
| Q64230889 | Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel |
| Q89639221 | Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist |
| Q90707736 | Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases |
| Q90422568 | Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury |
| Q90126673 | Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis |
| Q99579325 | Review: Pathogenesis of cholestatic liver diseases |
| Q92252696 | Role of the intestinal microbiome in liver fibrosis development and new treatment strategies |
| Q92609706 | SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
Search more.